Key result
Genetic ablation of cMyBP-C in mice resulted in increased postnatal cardiomyocyte cell cycling and proliferation that preceded the onset of cellular hypertrophy at postnatal day 9.
Population
cMyBP-C-/- mice and wild-type littermates on E129X1/SvJ background, evaluated from embryonic day 18.5 to…
Comparison
Genetic ablation of Mybpc3 vs Wild-type and heterozygous littermates
Design
Preclinical
Follow-up
Up to postnatal day 9 (PND9)
Authors
Loading...
Early proliferation may precede hypertrophy in cMyBP-C deficiency; leaves open whether cell-cycle targeting alters HCM onset in patients.
Absolute Event Rate: 59% vs 25%
p-value: p=<0.05
In a mouse model of hypertrophic cardiomyopathy, increased cardiomyocyte proliferation precedes cellular hypertrophy, suggesting early cell cycling contributes to cardiomegaly and may represent a unique therapeutic window.
Farrell et al. (2017) studied Hypertrophic cardiomyopathy. cMyBP-C genetic ablation vs. Wild-type (WT) mice was evaluated on Cardiomyocyte cell cycling (Ki67-positive cells per section) at postnatal day 1 (p=<0.05). Genetic ablation of cMyBP-C in mice resulted in increased postnatal cardiomyocyte cell cycling and proliferation that preceded the onset of cellular hypertrophy at postnatal day 9.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: